The Conference

 

World Drug Safety Congress Europe is the global leading strategy-led drug safety event for pharma and biotech organisations.


The three-day event will include case studies on proactive initiatives and new technologies being used in drug safety. Over the three days, you will meet with over 200 high calibre potential customers who need to find solutions around pharmacovigilance systems, regulatory compliance and case management.

 

This is the event to discuss the latest issues facing the drug safety sector, including:
 

  • Ensuring that new sources of safety information for signal detection and management are effective
     
  • Meeting regulatory standards and market specific PV requirements
     
  • How to involve patients better to develop drugs
     
  • Managing big data and its impact on pharmacovigilance

 

There will be truly visionary keynotes, panel debates, quality networking breaks, chat show panels, speed networking and roundtable discussions throughout the event.

We will share with you thoughts from the pioneers in drug safety. You will hear from:

  • Senior global executives involved in developing proactive pharmacovigilance initiatives
  • Heads of Evidence-based medicine and Big Data from all biopharma organisations
  • Leaders from regulatory, patient advocacy and technology fields who are advancing pharmacovigilance

 

 

We have now confirmed the conference tracks!

FUTURE OF PV

PV FOR ADVANCED TECHNOLOGIES

DETECTING SAFETY SIGNALS 

BENEFIT RSIK MANAGEMENT 

UPDATES ON PHARMACOVIGILANCE REGULATION

 

Early Confirmed Speakers

  • Sue Rees, EU QPPV, Executive Director, Global Safety, Amgen
  • Peter De Veene, Senior VP & Head of Global Drug Safety and Qualified Person for Pharmacovigilance, Grünenthal
  • Haris Shaikh, Director Safety Evaluation & Risk Management; Medical Director, GSK
  • Berit Nautrup Andersen, EU QPPV Director & Head of Global Drug Safety QPPV Office, Merck Biopharma
  • Betina Ostergaard Eriksen, Deputy QPPV, Novo Nordisk
  • Tanja Peters, Head PV Intelligence & Deputy EU QPPV, Boehringer Ingelheim
  • Sally Lee, Director of Pharmacodepidemiology EMEA / APAC, Celgene Europe
  • Dennis Vargo, Vice President and Head, Pharmacovigilance, TESARO
  • Jørgen Matz, Senior Director, Head of Medical Safety, Global Pharmacovigilance, Lundbeck
  • Jackie Roberts, Executive Director Regulatory, Pharmacovigilance and Medical, Actavis
  • Uwe Gudat, Head of Safety, Biosimilars, Merck Biosimilars
  • Mick Foy, Group Manager of Vigilance Intelligence and Research Group, MHRA 
  • Monika Manske, Lead Quality Management, PSRM, Pharmacovigilance Safety & Risk Management, Mylan Healthcare GmbH
  • Giovanni Furlan, EU QPPV, Helsinn Birex

 

  • Rudi Scheerlinck, Head Global Drug Safety, Basilea Pharmaceutica Ltd
  • Julia Appelskog, QPPV, Head of Pharmacovigilance, Bluefish Pharma
  • Sumit Munjal, Senior Medical Director, EU Marketed products, Global Pharmacovigilance, Takeda
  • Mircea Ciuca, Head Medical & Clinical Drug Safety, Vifor Pharma
  • Katharina Caspary, Director Pharmacovigilance, Head PV Partner Management and local PV, Horizon Pharma
  • Liana Gross-Martirosyan, Senior Pharmacovigilance Assessor, Dutch Medicines Evaluation Board Agency 
  • Jorge Borroto, Pharmacovigilance Officer, Ferrer
  • Steven Bailey, Vice President, Safety Surveillance & Risk Management, Research Unit / Vaccines, Pfizer
  • Logesvaran Yogendran, Vice President, QPPV and Head of International PV, Johnson & Johnson
  • Michael Richardson, VP International GPV&E and EU QPPV, Bristol-Myers Squibb
  • Susan Welsh, Chief Safety Officer, Sanofi (December 2016)
  • John Solomon, Head of Pharmacovigilance-UK & Ireland, Sanofi
  • Bruce Donzanti, Senior Group Director, Global Pharmacovigilance Innovation Policy, Genentech

 

 

GET THE SPONSORSHIP BROCHURE

 

 

Get involved

If you’d like to become an exhibitor, sponsor or speaker at the event
contact Edmond Rama  at edmond.rama@terrapinn.com
or +44 (0)20 7092 1052